title: The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
authors.affiliation: Myeloma Research Centre, Division of Molecular Pathology, The Institute of Cancer Research , London , UK.
authors.forename: Annamaria
authors.initials: A
authors.lastname: Brioli
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Melchor
authors.forename: Ian
authors.initials: I
authors.lastname: Titley
authors.forename: Gowri
authors.initials: G
authors.lastname: Vijayaraghavan
authors.forename: Claire
authors.initials: C
authors.lastname: Stephens
authors.forename: Athanasia
authors.initials: A
authors.lastname: Zeisig
authors.forename: Charlotte
authors.initials: C
authors.lastname: Pawlyn
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.forename: Ricardo
authors.initials: R
authors.lastname: Morilla
authors.forename: Faith E
authors.initials: FE
authors.lastname: Davies
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000187:drug effects* / Q000473:pathology; D005434:Flow Cytometry; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy*; D016019:Survival Analysis; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide